Biomarin Pharmaceutical BMRN Cash Flow Statement (2009-2026)

NASDAQ BMRN
$59.87 +0.41 (+0.69%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

Biomarin Pharmaceutical Quarterly Cash Flow Statement

Periods 69 quarters
Latest Jun 2026

Biomarin Pharmaceutical reported cash from operations of $168.11M and free cash flow of $139.29M for the quarter ended Jun 2026, down 9.3% year over year. This cash flow statement covers 69 quarters of results from Jun 2009 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2009 Sep2009 Dec2009 Mar2010 Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-36.49M-57.90M120.80M27.66M-6.65M-0.25M50.85M56.04M40.38M20.38M88.66M107.17M106.08M124.94M185.69M240.53M-30.74M-46.57M105.53M44.76M
Depreciation and DepletionDep. & Depletion
11.40M10.40M11.70M9.50M8.70M8.70M10.30M9.40M9.90M10.70M12.60M11.50M10.90M11.60M14.10M10.60M10.60M13.20M8.80M9.60M
Share-based CompensationStock Comp.
49.03M43.89M47.83M47.08M54.66M46.73M53.70M50.16M48.39M54.85M58.25M47.91M43.49M51.92M37.70M47.53M49.27M46.91M43.46M75.69M
Deferred Taxes
-13.22M-3.59M4.80M-1.34M-4.20M-51.34M-6.36M1.25M-15.03M-24.84M0.28M1.25M12.17M42.39M28.43M33.34M-13.65M0.61M9.22M-6.96M
Gains from Sales and DivestituresGains Divest
108.00M10.00M
Asset Writedowns and ImpairmentWritedown
12.65M25.96M14.20M5.68M2.97M122.05M
Cash from OperationsCash from Ops.
97.06M11.18M-45.43M56.23M158.32M6.79M-73.93M70.06M135.65M27.48M46.97M118.76M221.48M185.63M174.39M185.27M368.69M99.64M220.65M168.11M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
26.84M25.99M27.34M25.27M24.80M24.55M26.42M25.42M25.68M26.86M27.35M26.46M19.01M23.61M22.07M18.56M18.49M20.44M16.41M97.64M
Change in Working Capital
Change in ReceivablesChange Receivables
-48.09M-0.06M54.81M37.75M-38.81M28.28M138.80M7.04M-13.89M58.49M3.39M52.70M74.38M-72.55M57.59M98.53M-48.75M120.68M7.16M38.85M
Change in InventoryChange Inventory
25.50M15.94M-1.12M2.56M25.99M40.84M14.10M42.38M41.47M59.11M16.82M30.59M-18.15M34.27M24.34M48.13M26.33M18.13M-44.49M32.16M
Change in Accured ExpensesChange Accured Exp.
53.76M22.82M-78.14M1.80M73.95M61.42M-31.69M6.59M81.43M12.52M-59.01M4.75M122.28M-100.26M-2.65M5.77M116.37M-53.34M3.10M23.16M
Other Working Capital ChangesOther WC Changes
7.30M-2.73M8.01M3.99M-24.14M32.00M36.00M17.43M5.96M-9.05M17.35M5.53M8.96M41.86M6.33M8.77M17.59M5.89M11.55M12.04M
Investing Activities
Capital ExpendituresCapex
18.73M28.74M28.82M27.15M29.30M35.69M24.46M21.58M21.73M28.92M26.10M21.33M18.46M19.53M16.77M17.10M28.45M40.72M20.92M28.82M
Change in IntangiblesChange Intangibless
1.63M15.62M1.86M0.88M7.17M0.67M0.31M1.15M1.68M7.78M8.00M0.51M2.71M0.77M0.27M5.30M2.37M
Acquisitions
Cash from Investing ActivitiesCash from Investing
-119.85M-55.42M87.78M-29.70M-23.40M-54.71M-30.01M29.53M-45.80M-64.96M-14.24M90.48M-16.16M76.40M-28.24M-12.59M-330.96M-42.45M725.53M-5101.88M
Financing Activities
Other financing activitiesOther financing
5.70M1.38M32.95M11.43M6.32M3.59M51.42M16.44M4.54M3.92M49.95M16.79M5.91M4.91M38.78M12.31M2.18M2.70M28.18M37.42M
Cash from Financing ActivitiesCash from Financing
-1.03M14.40M-25.28M-11.78M7.54M10.87M-40.74M11.96M-0.79M10.84M-42.79M12.61M-499.12M2.86M-38.78M-4.60M-2.17M3.16M813.17M2,738.38M
Change in Capital Stock
Net Equity Issued and RepurchasedNet Equity Issued
5.24M16.32M8.23M21.26M14.37M25.47M21.17M29.02M4.36M14.80M7.20M29.42M4.80M7.86M7.71M0.01M6.75M
Additional items
Exchange Rate EffectFX Effect
-0.57M-0.02M1.09M-0.39M-0.75M0.07M0.23M2.75M1.97M-3.65M1.93M3.30M-2.90M2.50M-1.42M-3.06M0.74M1.22M1.41M-3.04M
Change in Cash
-24.39M-29.87M18.16M14.36M141.71M-36.98M-144.46M114.31M91.03M-30.29M-8.13M225.15M-296.70M267.39M105.96M165.01M36.29M61.57M1,760.76M-2198.43M
Free Cash FlowFCF
78.33M-17.56M-74.25M29.07M129.02M-28.90M-98.39M48.48M113.91M-1.43M20.87M97.44M203.02M166.10M157.63M168.17M340.24M58.92M199.73M139.29M
Net Cash FlowNCF
-23.82M-29.84M17.07M14.75M142.46M-37.05M-144.69M111.56M89.06M-26.64M-10.06M221.85M-293.80M264.89M107.38M168.08M35.55M60.35M1,759.35M-2195.39M

Biomarin Pharmaceutical Cash Flow Statement API

Pull Biomarin Pharmaceutical's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=BMRN&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY